New cancer drug trial halted after just 3 patients
Disease control
Terminated
This early-stage trial tested a new drug called AXN-2510 in adults with advanced solid tumors that had stopped responding to other treatments. The drug is a special antibody that targets two cancer pathways at once. However, the study was terminated early after enrolling only 3 p…
Phase: PHASE1 • Sponsor: Axion Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC